BMA Biomedicals

Founded in the late 1980s by a group of immunologists, our main area of activity is the development, production, and commercialization of antibodies. In 2005, BMA was acquired by Chemoforma AG, a long-standing business partner active in the production of immune-supporting feed additives. In 2013, BMA has expanded its product portfolio by integrating the comprehensive range of antibodies and ELISA kits from Peninsula Laboratories International, Inc. (PLII), offering researchers a broader selection of tools.